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1. Introduction 
 
James Parkinson has been the first to observe this disease in adults 
in the year 1817. In his essay entitled “An Essay of the Shaking 
Palsy” he described this disease as initiated with slow, progressive 
involuntary tremors, followed by difficulty in walking, swallowing and 
speech [1]. Apart from motor symptoms, Parkinson’s disease patients 
experience significant non-motor symptoms including mood and 
cognition decline, sleep disturbances, and other autonomic 
dysfunctions [2]. With the help of modern-day molecular and cellular 
research advancement, progressive degeneration of the dopaminergic 
(DA) neurons of the Substantia nigra (SN) brain region were found 
in Parkinson’s disease brains [3], in addition to the accumulation of 
misfolded protein aggregates. Both environmental factors and genetic 
mutations were suspected to cause PD [4,5]. One of the distinctive 
features of Parkinson’s disease is severe damage to the nigrostriatal 
dopaminergic system. Neurotoxic agents such as manganese and 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were suspected 
for this type of neuronal damage. MPTP induced Parkinson’s disease 
animal models were extensively used to study the neurodegeneration 
process as well as to identify potential therapeutic drug targets [6]. 
Soluble fractalkine (CX3CL1, chemokine ligand 1) isoform was 
shown to reduce impairment of motor coordination, decrease 
dopaminergic neuron loss, and ameliorate microglial (macrophages of 
brain) activation and proinflammatory cytokine release resulting from 
MPTP exposure [7]. 
Long time belief was that Parkinson’s disease etiology is sporadic 
(not genetically inherited) in nature. However, a small percentage of 
the  PD patients  were  now known to inherit gene mutations. Genes  
 
 
 
 
 
 
 
 
 
including ATP13A2, DJ-1, GIGYF2, HTRA2, LRRK2, PARK2 
(parkin), PINK1, SNCA and UCHL1 were associated with either 
autosomal dominant or recessive form of Parkinson’s disease [5]. 
From the listed genes SNCA (α-synuclein or α-syn) is critical to the 
pathogenesis in the early-onset of the rare familial form of PD. 
Insoluble form of α-syn fibrils were discovered in the protein 
aggregates called Lewy bodies (LBs), the hallmark pathological 
characteristics of Parkinson’s disease. The aggregation and 
accumulation of abnormal α-syn in dopaminergic neurons have been 
postulated to be responsible for the neurodegeneration that ultimately 
leads to cell death [8,9]. Synucleins were also found in the amyloid-
plaques in Alzheimer’s disease brains. In general, alpha-synuclein is 
highly expressed in brain at presynaptic terminals, particularly in the 
neocortex, hippocampus, striatum, thalamus, and cerebellum 
components. They function as molecular chaperones and interact with 
many proteins thus modifying their cellular activity. Due to its 
versatile interacting behavior, mutant alpha-synuclein has been 
implicated in the deregulation of many biological processes including 
oxidation, neuroinflammation, mitochondrial function, ubiquitination 
etc. [3,10–12]. Figure 1 depicts the various genes already implicated 
in Parkinson’s disease along with different deregulated biological 
processes caused by the several abnormal protein activities. 
To date, many genetic modifiers of PD and their role in PD 
pathogenesis have been described [13–17]. Some of these genes relate 
to neuronal growth and neuroprotective mechanisms in Parkinson’s 
disease. FGFs (fibroblast growth factors) have potent neurotrophic 
properties for dopaminergic neurons [18]. They promote DA 
neuron’s development and neurite outgrowth, rescue damaged DA 
neurons after different toxic insults, and prevent apoptosis. 
Overexpression of L1CAM (L1 cell adhesion molecule) enhances the 
survival of imperiled endogenous dopaminergic neurons in the 
Substantia nigra [19].  RAB3A (member of RAS oncogene family) 
has been shown to suppress α-syn toxicity in neuronal models of PD 
[20]. Fractalkines produced by neurons suppress the activation of 
microglia and play a neuroprotective role in 6-OHDA-induced 
(synthetic  neurotoxic  compound)   dopaminergic   lesions  [21].  In  
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general, metallothioneins (cysteine-rich, heavy metal-binding protein 
molecules) have been considered ‘defensive proteins’ with a role in 
neuroprotection. Metallothioneins 1 and 2 (MT1F, MT2A) have 
been shown to scavenge reactive oxygen species and free radicals in 
central nervous system [22]. 
Other genes have been implicated in PD pathogenesis. 
Neuroinflammation is suspected to play a major role in Parkinson's 
disease progression. MAPK signaling pathways contribute to 
neuroinflammatory responses and neuronal death triggered by 
synuclein-alpha aggregates or functional deficiencies in parkin or DJ-1 
genes in the pathogenesis of PD [23]. RNF11 (ring finger protein 
11) was suggested to play major role in the Parkinson’s disease 
pathology since it was found highly enriched in SN dopamergic 
neurons as well as its co-localization within Lewy bodies (abnormal 
aggregates of protein) in PD brains [24]. Earlier study by Galvin et 
al., (1999) had shown that β- and γ-synuclein are associated with 
hippocampal axon pathology in Parkinson's disease and dementia 
with Lewy bodies [25]. Recent genome-wide studies have found that 
mutations in at least 13 PARK loci and related genes increase both 
early- and late-onset PD susceptibility [15,26,27].  
Genome-wide approaches were also used to identify microRNAs-
target mRNA interactions in PD domain. MicroRNAs (miRNAs) 
are a class of small RNAs (~22 nucleotides) that act as post-
transcriptional regulators of gene expression by binding to the 
complementary sequences in target mRNAs. In recent years, miRNAs 
have emerged as potential drug targets in a variety of diseases 
including infections, metabolism and inflammation etc. [28]. A recent 
genome-wide miRNA profiling study for Parkinson’s disease has 
reported several miRNAs to be differentially expressed in PD blood 
samples. The hundreds predicted genes targeted by these miRNAs 
belong to various biological pathways including synaptic long-term 
potentiation, semaphorin signaling in neurons and protein 
ubiquitination pathway, etc., many of which were previously found 
deregulated in Parkinson’s disease mechanism [29]. 
Figure 1. Biological processes and genes implicated in the Parkinson’s disease. Courtesy: Parkinson’s disease pathway from KEGG database, retrieved on April 
3, 2013. 
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Even though there were some new treatment options available to 
PD patients, oral administration of levodopa (precursor of dopamine) 
has been the gold standard medication for Parkinson’s disease. But 
prolonged use of levodopa increases the risk of developing 
levodopa‐induced dyskinesias (involuntary movement) [30,31]. 
Recently, deep brain stimulation (DBS) has been offered as a 
secondary treatment option in Parkinson’s disease where the benefits 
of medication have failed/diminished. DBS therapy has been shown 
to increase the neuron firing rate, blood flow and to promote 
neurotransmitter release as well as to stimulate neurogenesis. Although 
deep brain stimulation improves the motor symptoms of Parkinson’s 
disease, it is a serious surgical intervention with major side effects of 
infection and intracranial hemorrhage including the risk of death [32].  
In our study we construct a variety of biomolecular networks 
proceeding from several gene expression datasets covering different 
areas of brain affected by Parkinson’s disease. Two such sets were 
reported by Moran et al. in 2006, who provided a whole genome 
analysis of the Substantia nigra (SN), found considerable difference in 
the gene expressions compared to control, reported several new genes 
that map to PARK loci, and identified 570 “priority genes” after 
using the Benjamini-Hochberg FDR correction [33]. Two years later, 
the same group published a network-based analysis based on Pathway 
Studio’s ResNet database version 5.0. Several direct interaction 
networks have been constructed for the interactions between priority 
and known-PD genes. Cancer, diabetes and inflammation disease 
conditions have been associated with the top up-regulated priority 
genes. Another set was published by Zhang, et al. in 2005 [34], 
highlighting some of the deregulated genes responsible for either 
disease aggravation (MKNK2) or neuroprotection (HSBP1, SMA5, 
and FGF13). Deregulation was noticed in various genes belonging to 
metallothionein group and the heat shock protein group. These 
patterns of multiple molecular process deregulations have been found 
across different brain regions studied. Another expression pattern 
discovered supports the hypothesis for ubiquitin/proteasome system 
(UPS) dysfunction in Parkinson’s disease. A decrease in Complex I 
activity has also being found to reinforce the suspected mitochondrial 
deregulation in PD.  
With current advancement of different “omics” technologies 
along with effective in-silico testing options, finding successful 
molecular therapeutic targets for Parkinson’s disease seems much 
closer than before. Along this avenue, the current paper presents a 
comprehensive network-based analysis of Parkinson’s disease (PD) 
related microarray datasets. Helped by the latest accumulated 
knowledge of gene/protein interactions and sophisticated software 
for network analysis we were able to expand upon the previous 
analyses of this disease paradigm, underlying cellular mechanisms and 
critical molecular players, as well as to identify novel drug targets. 
This research work on Parkinson’s disease is part of a broader 
network-based data analysis of three neurodegenerative disorders 
(NDDs) including Alzheimer’s (AD) and Huntington’s disease (HD) 
with the final goal the identification of unified underlying molecular 
mechanisms of these three devastating NDDs. Manuscripts outlining 
our research findings of AD and HD, including the unified molecular 
mechanisms of NDDs, are in preparation and will be submitted for 
publication subsequently. 
Figure 2. The study workflow. 
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2. Methods and Data 
 
The work flow followed in this study is illustrated in Figure 2. 
 
DNA microarray is a powerful technology that provides a high 
throughput and detailed view of the entire genome and transcriptome 
of an organism by measuring the relative mRNA abundance intensity. 
Due to their ready availability, high volume capacity and parallel 
testing, microarrays have dramatically accelerated many types of 
molecular biology investigation. The known limitation of using 
microarrays is that mRNA level does not necessarily correlates with its 
functional protein level in the cell. Also, post-translational 
modifications essential for determining protein function are not 
present on DNA microarray. However, these limitations could be 
partially overcome by careful handling of arrays, probe selections and 
repeat experiments. Moreover, microarray assays are inexpensive and 
less-time consuming when compared with proteomics experiments. 
Better results in understanding the underlying biological mechanisms 
are yielded by integrating gene expression a l o ng  w i t h  proteomics 
da t a .  S uch  h i gh  q ua l i t y  p ro t eomi c  da t a  a r e  e xpec t e d  t o  be  
p rov ided  b y  the Human Brain Proteome Atlas, a project launched 
by 10th HUPO World Congress in 2011 [35]. 
Microarray gene expression of post-mortem brain tissue samples 
from diseased and control conditions were used. The three Affymetrix 
GeneChips sets used were GSE8397 U133A and U133B 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE8397) 
and GSE20295 U133A 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20295) 
arrays. This specific selection was influenced by our extended research 
plan to search for the unified underlined mechanism of 
neurodegenerative diseases. Only Affymetrix post-mortem datasets 
were found to cover the three most characteristic neurodegenerative 
diseases - Parkinson’s, Alzheimer’s and Huntington ones. The samples 
were initially selected after careful review of the cases 
neuropsychological and/or neuropathological data, and matched by 
age and sex. The control subjects were with no known 
neurodegenerative disease history. The GSE8397 arrays included 15 
cases and 8 controls each with male to female ratios 9:6 and 6:2, 
respectively. The mean age of cases reported was 80±5.7 whereas that 
of controls 70.6±12.5. The brain tissues/regions involved were 
Superior Frontal Gyrus (SFG), Medial Substantia Nigra (MSN) and 
Lateral Substantia Nigra (LSN). The GSE20295 array has equal 
number of 15 cases and controls. The male to female ratios for the 
two groups were 9:6 and 10:5, while the mean age was 76.7±6.2 and 
71.2±11.1, respectively. Broadman Area 9 (BA9), Putamen (PT) and 
Substantia Nigra (SN) were the brain tissue/regions involved.  
 
The microarray data analysis was focused on genes differentially 
expressed across different tissues. For consistency between the selected 
datasets, the latter were subjected to the same techniques for pre-
processing, normalizing and post-normalizing. Bioconductor software 
for analysis and comprehension of genomic data based on R 
programming language [36] (http://www.bioconductor.org/) was 
implemented in written in-house R. The raw microarray CEL files 
were downloaded from the GEO/ArrayExpress databases, and the 
microarray chip quality was assessed using arrayQualityMetrics [37]. 
More specifically, GeneChip reproducibility was assessed, signal-to-
noise ratio was determined and no extreme outliers were detected. 
Relevant quality assessment figures/plots were obtained 
 
(a) 
 
 
(b) 
 
 
(c) 
 
 
 
 
 
 
All microarray expression datasets were normalized to correct for 
systematic differences due to sample preparation, batch processing, 
etc. between genes or arrays. A multi-array average (RMA) expression 
measure was used  [38], which consists of three steps: background 
correction, quantile normalization (each performed at the individual 
probe level), and robust linear model fit using median polish (log-
transformed intensities at the probesets level). The standard RMA 
Figure 3. Four-set Venn diagram of the overlap of significantly 
differentially expressed genes (SDEGs) in (a) GSE8397 HG-U133A (b) 
GSE8397 HG-U133B and (c) GSE20295 HG-133A gene expression datasets. 
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approach was utilized to enable more direct comparisons with other 
similar research results.  
The differential gene expression changes were statistically 
evaluated by the empirical Bayes (eBayes) method [39] from the 
limma Bioconductor package. Probe-sets with p-values < 0.05 were 
considered to be significantly differentially expressed genes (SDEGs). 
R source code for statistical analysis of such microarray gene 
expression dataset, including graphical output of the differentially 
expressed gene, can be obtained from the authors by request.  
 
The microarray datasets were subjected to the same statistical 
procedures given above and significantly differentially expressed genes 
lists called “seed genes” were generated for each dataset. The lists 
generated from the GSE8397 dataset were denoted as SFG, MSN 
and LSN, for the three types of brain tissue samples: superior frontal 
gyrus, medial and lateral Substantia nigra, respectively. In addition, 
differential gene expression changes found between control and PD 
cases irrespective of tissue types were denoted as “Diagnosis”. An 
overlap of 414 seed genes was found between the four sets of 
significantly differentially expressed genes (SDEGs), as shown in 
Figure 3a. In a similar way, an overlap of 225 seed genes was found in 
the GSE8397 HG-U133B microarray gene expression dataset (Figure 
3b). Altogether, 631 seed genes were found after removing duplicates 
in GSE8397 U133A and U133B datasets. 
Correspondingly, using GSE20295 HG-U133A (Figure 3c) 
microarray dataset another four sets of seed genes, namely diagnosis, 
BA9, PT and SN (for tissue samples used), were generated and an 
overlap of 110 genes were considered SDEGs (p-values < 0.05). 
Finally, combining the three Parkinson’s microarray datasets 
(GSE8397 (HG-U133A and B) and 20295) we found a total of 719 
(p-values < 0.05) genes to be significantly differentially expressed.  
The p-values shown above were obtained with paired p-test 
without correction for multiple correlations. Due to the specificity of 
the post-mortem expression datasets no statistically significant 
expressed genes were found after Bonferoni correction, while with the 
less stringent Benjamini-Hochberg correction the number of SDEGs 
was not large enough to allow for meaningful analysis. However, to 
compensate partially for not taking into account the probes 
correlation, we selected to consider a more stringent p-value cut-off of 
0.01 for the paired p-test value. With the new cut-off the total 
number of “seed genes” for Parkinson’s disease was reduced from 719 
to 267 (see Supplementary Table S1 for details). 
 
For constructing and analyzing networks relevant to 
neurodegenerative diseases we selected Pathway Studio 9.0 software 
package [40], (http://www.elsevier.com/online-tools/pathway-
studio). It offers options to construct various kinds of networks such 
as direct interaction, shortest-path, common targets and regulators of 
pairs or multiple genes, and others. The molecular interaction data 
used in the study were supplied by the ResNet 9.0 database (released 
October 15, 2011), provided jointly with the software. It covers 
human, mouse and rat proteins. The database is compiled by using 
MedScan technology from over 20 million NCBI’s PubMed abstracts 
and over 880,000 full-text articles as of May 27, 2011. Currently the 
database covers 125342 entities, such as cell process, complex, disease, 
functional class, treatment and small molecules including over 
110000 genes/proteins. It offers over a million interactions like 
binding, chemical reaction, direct regulation, expression, miRNA 
regulation, molecular synthesis, molecular transport, promoter 
binding, protein modification and regulations, as well as   information 
about almost 5600 custom built cell-processes, metabolic and 
signaling pathways. 
In this study, we constructed direct interaction (DI) and shortest-
path (SP) networks to analyze interactions between the SDEGs and 
with connecting genes/proteins that could be of interest in 
neurodegeneration process. Direct regulatory interactions of five 
different types were used only, including among others promoter 
binding, protein modification and miRNA regulation  
By applying the shortest-path (SP) network strategy with the list 
of SDEGs, we were able to identify connecting genes/proteins that 
might contribute to the neurodegenerative process but have not been 
related so far to it. This approach is based on the inference that 
genes/proteins with well-defined biological functions when 
interacting with other genes/proteins known of importance for given 
disease like Parkinson’s have a higher probability to share that 
function, as compared to those selected at random (guilt-by-
association). One limitation of the shortest-path network approach is 
that sometimes it could bring in a large amount of intermediary nodes 
in order to have a unified network. Such a huge network is not only 
impractical for further analysis, but it also diminishes the importance 
of the seed genes in the selected scenario. Thus, care was taken to 
reduce the number of connecting nodes in the shortest-path network 
producing compact shortest-path networks. The last task was 
accomplished by setting up a cut-off rule, to include only seed genes 
with a large number (≥ 25) of neighbors in the Pathway Studio 
ResNet 9.0 database, thus focusing on genes having a better chance to 
be connected to known Parkinson’s disease genes. The 267 seed genes 
were thus reduced to 105 genes and the ratio of connecting to seed 
genes/proteins ranged from 1.5:1 to 2:1 for all the datasets.  The 
construction of the compacted SP network was finalized by adding 
few generic genes without which some of the genes of interest would 
still remain unconnected.  
Special attention in the network analysis was paid to identifying 
the key players - nodes with high network topology scores of node 
degree (local connectivity), closeness centrality (network monitoring) 
and betweeness centrality (traffic-influential) scores [41]. The 
calculation of these topological descriptors was executed with the 
Pajek software package [42]. Nodes with such favorable topological 
characteristics, along with biological/ molecular functions relevant for 
the neurodegenerative process, have been considered in two categories 
“already known PD-genes” and “genes of interest for PD”. The 
distinction was made by using sources like Online Mendelian 
Inheritance in Man (OMIM) database (http://omim.org/), NCBI’s 
PubMed database (http://www.ncbi.nlm.nih.gov/pubmed.com), 
MalaCards database (http://malacards.org/), and Google search for 
the latest publications (http://www.google.com). Each of these two 
categories were further divided in two subcategories, those found 
among the significantly differentially expression genes (SDEGs) and 
such emerging from the connecting proteins in shortest-path and 
common regulator networks.   
Differential gene expression was analyzed through complex 
regulatory networks that are controlled by two types of regulators: 
transcription factors (TFs) and microRNAs (miRNAs). In order to 
identify the microRNAs that target our seed genes we constructed 
shortest-path network with only miRNA regulation type of 
interactions using Pathway Studio’s ResNet 9.0 database.Then, in 
order to construct a miRNA regulatory network we used the direct 
interaction network option in Pathway Studio utilizing the seed genes 
and the corresponding miRNAs identified in the earlier step. We 
identified many microRNA regulations of our seed genes which will 
be discussed in detail in the following sections. The microRNA 
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regulatory network also revealed an integrated regulation in 
neurodegeneration process by both transcription factors and 
microRNAs. However, the miRNA regulatory analysis should be 
offered with some caution, because currently a high percentage of 
miRNA-mRNA interactions in Pathway Studio ResNet 9.0 database 
are based on predictions but not on experimental validation. 
  
Gene ontology (GO), an expert-curated database, assigns a list of 
genes into various biologically meaningful categories such as 
biological process, molecular function, and cellular component. p-
values are used to rank the significantly modulated genes into GO 
categories. We used the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) [43–45], which provides biological 
functional interpretation of large lists of genes derived from genomic 
studies such as microarray, proteomics experiments, etc. Core analysis 
in Ingenuity’s IPA (Ingenuity Systems, www.ingenuity.com) and 
Pathway Enrichment Analysis in Pathway Studio were then applied to 
identify enriched canonical pathways in Parkinson’s disease, and the 
genes from the lists of SDEGs and network generated lists that take 
part in the enriched pathways. 
 
The results from DAVID analysis were examined in an attempt to 
characterize the integrated molecular mechanisms involved in 
neurodegeneration process. The output includes those GO categories 
and KEGG pathways that are enriched in a given list of genes. Kyoto 
Encyclopedia of Genes and Genomes (KEGG) is a basic database 
resource for understanding high-level functions of biological systems 
from molecular-level information, especially large-scale molecular 
datasets generated by genome sequencing and other high-throughput 
experimental technologies (http://www.genome.jp/kegg/) [46]. The 
KEGG pathways that were significantly enriched (p-value ≤ 0.05 
after Benjamini-Hochberg FDR adjustments) and previously known 
in neurodegenerative disorders under study were identified and further 
investigated. Google and NCBI’s PubMed databases were used to 
search for such previously known biological pathways in 
neurodegenerative disorders. After that, all the genes from the 
enriched KEGG pathways were combined into a list of “mechanism 
genes”.  Based on their molecular functions we further classified these 
“mechanism genes” as either disease causing (leading to neuronal 
loss/death) or disease alleviating (helps in neuronal survival) agents. 
Once again, Google and NCBI’s PubMed databases were used to 
identify such previous implications. For easy understanding, the loss 
versus survival classification is represented in the figures of next 
sections by highlighting the “mechanism genes” in purple or yellow, 
respectively. Using the “mechanism genes” direct interaction network 
was constructed as well as investigated for integrated disease 
mechanism. As will be shown in Section 3 we outlined three possible 
mechanisms for initiating the Parkinson’s disease from extracellular 
signaling. 
 
3. Results 
 
We initiated our Parkinson’s disease network analysis using the 
267 “seed genes”, selected as explained in Methods and Data. Out of 
the 267 significantly differentially expressed genes (SDEGs) 67 genes 
were directly connected to each other by interactions such as 
regulations, promoter binding, direct regulation, protein modification 
and miRNA regulation. This interaction network (Figure 4) has a 
relatively low average node degree of 2.84. Genes like MAPK8, 
RAB3A, STXBP1, SYN1 and VAMP2 are the top five most highly 
connected nodes with node degree ≥ 7. One of the well-known 
Parkinson’s gene SNCA (α-synuclein) was among the top five most 
influential (betweeness centrality) and highest accessible (closeness 
centrality) nodes in the network. 15 of the 67 genes/proteins 
(ACHE, ATR, CX3CL1, FGFR1, GRIA1, L1CAM, MAPK8, 
MT1F, MT2A, PRDX2, RAB3A, RNF11, SNCA, SNCG and 
SPTAN1), have already been implicated in Parkinson’s disease 
paradigm either as neuroprotective and therapeutic agents or as disease 
aggravating ones. In Figure 4, these previously PD-known genes are 
highlighted in green. 
Based on their characteristic physiological roles 12 genes (BSN, 
DCLK1, KCNQ2, NCAM1, NEDD4L, PAK1, PCDH8, STXBP1, 
SYN1, UBE2N, UNC13A and VAMP2) colored in blue in Figure 4 
were classified as potentially involved in Parkinson’s disease. The 
molecular functions of some of these candidate genes are summarized 
here. NCAM1 (neural cell adhesion molecule 1) is important in 
cognitive processes such as learning and memory. It plays a major role 
in brain immune surveillance system [47]. NCAM1 also facilitates the 
release, repositioning, and/or expansion of the synaptic complex. 
BSN (bassoon presynaptic cytomatrix protein), is a scaffolding 
protein involved in organizing the presynaptic cytoskeleton, the 
specialized sites where neurotransmitters are released from the 
synaptic vesicles. (Retrieved on 25-Feb-2013 from 
http://www.ncbi.nlm.nih.gov/gene/8927). Campbell et al., (2012) 
[48] have shown that STXBP1 (syntaxin binding protein 1) is a vital 
part of the process of calcium ion–dependent exocytosis in neurons, 
as well as in neuroendocrine cells. It facilitates membrane fusion and 
neurotransmitter release.  SYN1 (synapsin I) is known to be a key 
player in synapse formation and plasticity [49]. During an action 
potential (an important part of the neuron firing process), synapsins 
are phosphorylated by PKA (cAMP dependent protein kinase), 
releasing the synaptic vesicles and allowing them to move to the 
membrane and release their neurotransmitter.  VAMP2 (vesicle-
associated membrane protein 2), gene is thought to participate in 
neurotransmitter release at a step between docking and fusion. A 
recent study has shown that single nucleotide polymorphisms in 
UNC13A (unc-13 homolog A) gene may be associated with sporadic 
amyotrophic lateral sclerosis (ALS) [50]. It regulates neurotransmitter 
release at synapses, including at neuromuscular junctions. α-synuclein 
was shown to promote disruption of ubiquitin proteasome system 
[51]. UBE2N (ubiquitin-conjugating enzyme E2N) targets proteins 
for degradation via the proteasome. In recent years, synaptic vesicle 
trafficking defects have been increasingly implicated as an important 
factor in many PD models, either via direct interactions with the 
synaptic vesicle (SV) cycling machinery or via indirect effects caused 
by mitochondrial dysfunction [52]. Even though genes BSN, 
NCAM1, STXBP1, SYN1, VAMP2 and UNC13A are not shown 
to be directly related to PD, they all seems to play an important role 
in the regulation as well as the release of neurotransmitters and 
synaptic vesicles  during the SV cycle process. 
Additional arguments for considering the above mentioned genes 
as associated with Parkinson’s disease are provided from network 
perspective. Figure 4 reveals that BSN, STXBP1, SYN1, VAMP2, 
and UNC13A directly interact with RAB3A, a gene well-known in 
PD, where RAB3A is able to provide substantial rescue against α-syn-
induced degeneration of dopaminergic neurons. Besides with RAB3A, 
SYN1 is also directly connected to GRIA1 and SNCA, two known 
PD genes. Studies have suggested glutamate receptor (GRIA1) 
antagonists as potential treatment agent for Parkinson's disease [53]. 
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In the direct interaction network, potential candidate genes like 
PAK1 and UBE2N are among the top five nodes with high closeness 
(visibility) centrality score. Another of the proposed candidate genes 
SYN1, was among the top five hub nodes as well as among the top 
five nodes with highest betweenness (traffic-influential) centrality 
score. Being a first-level direct interacting neighbors of a known gene 
(guilt-by-association), makes also BSN, NCAM1, PAK1, PCDH8, 
STXBP1, SYN1, UBE2N, UNC13A or VAMP2 genes of potential 
interest in Parkinson’s disease. The physiological role these genes play 
in synaptic vesicle trafficking, neurotransmitter release, and 
ubiquitination, as well as their other network attributes like being 
hubs, network traffic-influential and/or monitoring nodes, increases 
the chance of these genes to be involved in the PD pathology, which 
reinforces the arguments in favor of their experimental validation. 
 
A shortest path network (SP) was built by selecting 105 out of 
the 267 significant differentially expressed genes (SDEGs), which 
have a higher chance to be connected to some of the known PD genes 
(See Methods). Interaction types included promoter binding, protein 
modification and direct regulation. 193 genes were added by the 
Pathway Studio 9.0 software to connect the 105 seed genes along the 
shortest paths between any pair of genes. The connecting genes were 
examined in sources like OMIM and PubMed, along with Google 
search to verify whether they have already been implicated or not in 
PD. In the second case, whether they could be of potential interest in 
PD diagnosis was decided based on the gene’s physiology/molecular 
characteristics and network location (guilt-by-association).  
A more compact version of this 298 genes SP type network was 
constructed using only the genes from the four categories of Table 1, 
and adding few generic genes without which some of the genes of 
interest would remain unconnected. The compact SP network (see 
Figure 5) is considerably better connected (average node degree 6.79) 
than the one based on direct interactions. Many of the known PD 
genes, such as AKT1, CASP3, CDK5, MAPK1, MAPT and SNCA 
are highly connected in this network. From those, CDK5 and 
MAPK1 are among the 10 hub genes (AKT1, CASP3, CDK5, 
CREB1, CTNNB1, EGFR, MAPK1, SP1, SRC and TP53) with 
node degree > 15. In biomolecular networks highly connected nodes 
tend to be part of critical functions or pathways, some of the found 
hubs like TP53, MAPK1, AKT1 and CASP3 being a typical 
example. 
 
 
 
Figure 4. Parkinson's disease direct interaction network. The 15 genes/proteins implicated previously in PD pathology are highlighted in green and the 12 
genes/proteins of potential interest for that disease are highlighted in blue. Different interactions are represented as follows: regulation – dashed grey, 
molecular transport – dotted red, co-expression – solid blue, protein modification – solid green, and protein-protein binding – solid purple.  
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The nodes included in the network were then subjected to 
enrichment analysis using DAVID software tool which systematically 
maps the given gene list to the associated biological annotation terms. 
The statistically significant enriched Gene Ontology categories and 
pathways related to brain and nervous system, assessed with the 
Benjamini-Hochberg multiple correction, are presented in Table 2. 
Several clusters of genes were thus identified to be involved in neuron 
development, differentiation, projection and apoptosis, synaptic 
transmission, vesicle transport and regulation as biological processes 
affected by Parkinson’s disease. Indeed, many of the enriched genes 
like CDK5, FGFR1, L1CAM, NR4A2, PRKCA, RAB3A, RAC1 
and SNCA have already been studied as mediators, suppressors or 
regulators of neurodegeneration. Pathways such as ErbB signaling and 
Neurotrophin signaling are enriched in this PD related gene list. Both 
these pathways were considered as major avenues to promote survival 
of dopaminergic neurons [54]. Synaptosomes, axons, and membrane-
bounded vesicles are some of the cellular components that are found 
affected by PD. 
Table 3 lists the genes identified in our study as possibly related 
to Parkinson's disease, based on their moderate-to-considerably high 
connectivity to known PD genes. CTNNB1 (catenin, beta 1) has the 
record environment of ten (!) nearest neighbors in the compacted 
shortest path network (CSPNW, Figure 5) all of which known to be 
involved in Parkinson’s disease (AKT1, CASP3, CASP6, CDK5, 
Figure 5. Parkinson's disease compact shortest path network. The genes/proteins implicated in PD pathology are highlighted in green and red. The 
genes/proteins of potential interest are highlighted in blue and orange (green and blue refer to SDEGs, while red and orange to SP network connecting genes, 
respectively). Different interactions are represented as follows: protein modification – solid green, promoter binding – dotted green and direct regulation – 
solid grey.  
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CREB1, MAPK8, NR4A2, PTEN, RAC1 and SMAD3). This 
makes CTNNB1 number one candidate gene of interest. This gene, 
along with Wnt1 and Fzd-1 critically contributes to the survival and 
protection of adult midbrain DA neurons [55]. In addition, it has a 
high betweeness centrality which increases its global influence in the 
network.   
 
 
 
 
The next strongest candidate for implication with Parkinson’s 
disease is EGFR (epidermal growth factor receptor) gene having six 
PD-related neighbors (CASP3, CDK5, PRKCA, RNF11 and TP53). 
It is one of the top ten nodes with highest node degree, closeness as 
well as betweeness centrality scores. This greatly contributes EGFR to 
be one of the critical positions in the compact shortest path network 
with greater visibility and traffic-control. Many studies have shown 
that EFGR signaling play a major role in neurogenesis, neuron 
survival and maintenance [56–59]. In a recent study, EGFR has been 
suggested as a preferred target for treating amyloid-beta induced 
memory loss in Alzheimer’s disease [60]. 
Third interesting PD candidate is PAK1 (p21 protein 
(Cdc42/Rac)-activated kinase 1) gene having five PD-related 
neighbors (AKT1, CASP3, CDK5, RAC1, and TP53).  PAK1 
regulates neuronal polarity, morphology, migration and synaptic 
function [61]. The gallery of Parkinson’s disease potentially related 
genes from Table 3 includes also CEBPA (CCAAT/enhancer binding 
protein (C/EBP), alpha), which interacts with four known PD genes 
(GATA2, IL12B, MT2A, and TP53). CEBPA has been shown to 
bind to the promoter and modulate the expression of leptin, a 
hormone having easy accessibility to the brain. It is important to note 
that leptin receptors are expressed in neurons and other brain regions 
and are known to regulate neural development. Thus, leptin could be 
a potential drug candidate for neurodegeneration [62].  
The compact shortest path network included many noteworthy 
connecting proteins like APP, CREB1, HSP90AA1, MAPT and 
PTEN which were previously implicated to play critical roles in many 
neurodegeneration disease pathogenesis and couple of them were 
indicated to have neuroprotective mechanism. APP (amyloid beta 
(A4) precursor protein), is the major component of the filamentous 
inclusions found in the Lewy bodies and Lewy neuritis, the 
characteristic hallmark features of many neurodegenerative diseases 
including Parkinson’s, Alzheimer’s, dementia with Lewy bodies and 
multiple system atrophy (MSA). Neurodegenerative diseases caused 
by abnormal aggregations of alpha-synuclein proteins are specially 
classified as alpha-synucleinopathies [63–66]. Similarly, tauopathies 
are a class of neurodegenerative diseases that are associated with the 
aberrant accumulations of tau proteins (MAPT) in the brain. Hyper 
phosphorylated tau proteins are the main component of 
neurofibrillary tangles (NFTs), another typical pathological feature of 
neurodegeneration. Tau proteins deformation are found in both 
genetic and sporadic forms of Parkinson’s and Alzheimer’s diseases in 
addition to other neurodegenerative diseases such as progressive 
supranuclear palsy (PSP),  Down’s syndrome,  Pick’s disease [67–70].  
A Network View on Parkinson’s Disease 
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Many molecular evidence suggests potential interaction between 
alpha-syncluein and tau proteins [71]. PTEN gene mutations also 
contribute to the NFT formations and the deregulation of tau 
phosphorylation [72–74]. Detailed biochemical and genetic studies 
about APP, MAPT and PTEN molecular processing will be crucial 
to the development of therapeutic targets to treat many 
neurodegenerative diseases. 
CREB1 and HSPs were suggested for such therapeutic measures 
in neurodegenerative disorders. In a mice model study [75], it is 
indicated that postnatal disruption of CREB1 along with CREM 
showed progressive neurodegeneration in the hippocampus and in the 
dorsolateral striatum. This evidences that both CREB1 and CREM 
can promote nerve cell survival globally in developing brain while 
more selectively in adult brain. Earlier studies have demonstrated that 
increase in the expression of HSPs, and especially HSP70, by gene 
transfer or HSPs inducers can reduce the aberrant protein misfolding 
and inhibit the pro-apoptotic pathway to attenuate dopaminergic 
neuron degeneration [76].  
Besides being major contributors of neurodegeneration process, 
APP, CREB1, HSP90AA1, MAPT and PTEN have varying degree 
of interactions with many known Parkinson’s disease genes (see 
CSPNW, Figure 5). Among these five genes, CREB1 appears to have 
major network advantage as being one of the top ten nodes with 
highest local connectivity, visibility and traffic-influential node in the 
compact shortest-path network. In addition, genes like APP, MAPT 
and HSP90AA1 are among the top 25 nodes with highest 
connectivity and higher accessibility to all other nodes as measured 
from their node degree and closeness centrality score. Other genes 
from Table 3 might also be investigated for possible relations to 
Parkinson’s disease, including the generic genes MAPK1 and EGFR, 
which are also interacting with many known PD genes.  
 
The genes used to construct the compact shortest-path network 
were subjected to Ingenuity’s IPA and DAVID pathway enrichment 
analysis, the latter software utilizing KEGG pathway classifications 
(Kyoto Encyclopedia of Genes and Genomes,  
http://www.genome.jp/kegg/) [46]. IPA produced 25 enriched 
pathways vs. 34 for DAVID, and after elimination of the cancer- and 
infection disease- related pathways, the ratio reduced to 18:21. After 
reviewing Parkinson’s disease literature we selected sixteen of the 
David enriched pathways (Table 4) belonging to categories of signal 
transduction, cell motility, cell communication, immune system, 
nervous system and neurodegenerative diseases.  
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Directly shared between IPA and DAVID were the pathways for 
p53, axonal guidance, gap junction and adherence junction signaling. 
Many signaling pathways (see Figure 6) including 14-3-3 mediated, 
neuregulin, semaphorin, ephrin, gap-junction, axonal guidance, as well 
as different growth factor signaling like EGF/EGFR, FGF, and NGF, 
were found enriched in Parkinson’s disease pathology. This finding 
extends over the recent report [77]. Neuregulins along with epidermal 
growth factors play a diverse role in neuronal development and 
differentiation. Systemic administration of neuregulin-1β1 protects 
dopaminergic neurons in a mouse model of Parkinson's disease [78]. 
Semaphorins and ephrins are prominent families of axon guidance 
cues during normal nerve growth and also after injury. Binding 
interactions were reported between 14-3-3 proteins Synuclein-alpha 
and LRRK2 (leucine-rich repeat protein kinase 2), genes linked to 
sporadic and familial form of PD [79].  It was symptomatic to find 
out major neurodegenerative conditions like Alzheimer’s disease, 
Amyotrophic lateral sclerosis (ALS) and Huntington’s disease 
signaling, to be enriched in Parkinson’s disease conditions as well. 
Discovering these overlapping pathways will help to better understand 
the complex neurodegenerative diseases mechanism and to search for 
therapeutic agents common for the entire family of these diseases.  
The analysis of genes involved in the selected DAVID/IPA 
pathways revealed more genes related to Parkinson’s disease 
manifestation, such as FYN (protein-tyrosine kinase oncogene 
belonging to focal adhesion pathway) and VEGF (from VEGF 
signaling pathway). FYN-mediated signaling [80], activates 
phosphorylation of alpha-synuclein, and the accumulation of this 
phosphorylated protein in the brainstems of patients with Parkinson’s 
disease is a signature mark of this disease. VEGF (vascular endothelial 
growth factor) is known to promote microglial proliferation, 
neurogenesis and angiogenesis providing thus neuroprotective effects 
via both direct and indirect mechanisms with other players of VEGF 
signaling pathway [81]. This was one more argument to use the 46 
genes/proteins found in common in all the 16 KEGG pathways from 
Table 4 as an essential part of the integrated Parkinson’s disease 
mechanism. The network built on this basis is shown in Figure 7. 
The genes in Figure 7 are classified into four categories as being 
already implicated in Parkinson’s disease, such of potential interest to 
PD, as well as being disease causing (leading to neuronal loss/death)  
or disease alleviating (helping in neuronal survival. Due to the high 
network interconnectedness no separation between the loss and 
survival genes could be detected; the genes appear as part of a single 
integrated system. Visual inspection of the pathways in KEGG 
database also revealed that there is no definite compartmentalization 
of processes within a biological cell. One process/pathway feed into 
another or multiple pathways, e.g., WnT signaling pathway includes 
players from MAPK, focal adhesion, adherens junction, and 
Alzheimer's disease pathways. 
In examining the integrated mechanism network three routes 
emerged for triggering the Parkinson’s disease mechanism via one of 
the extra-cellular ligands CX3CL1, IL12B and SEMA6D. In the first 
route, CX3CL1 (fractalkine) together with DRD1 (dopamine 
receptor D1) suppresses the expression of ionotropic glutamate 
receptor GRIA1. There is also interaction between CX3CL1, 
ADAM17 (metallopeptidase domain 17), and LCAM1 which then 
follows a downstream path into cytoplasm and to the nucleus for 
subsequent regulation of gene expression. ADAM17 and TP53 
activate  the  expression of  the  upstream  positioned  CX3CL1. The  
Figure 6. Parkinson’s disease enriched canonical pathways as produced by IPA analysis. 
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suppression of microglial activation by fractalkine contributes to 
neuronal survival. ADAM17 mediated fractalkine cleavage would 
ultimately limit activation of microglia and support neuronal survival 
[82]. There is a two-ways gene expression modulation between 
CX3CL1 and SRC. Inside the cytoplasm AKT1, CASP3, MAPK1, 
MAPK8 genes/proteins are direct downstream targets of CX3CL1.  
Except GRIA1 and CASP3, all other downstream target genes of 
CX3CL1 are positively activated by it. Some of the players in the 
outlined route like ADAM17, CX3CL1, DRD1, GRIA1, and 
LCAM1 have been claimed in animal model studies as therapeutic 
targets for Parkinson’s disease [19,21,83,84]. 
Second route is initiated via SEMA6D and its receptor PLXNA1 
(plexin A1) which in turn regulates RHOA and AKT1 gene 
expression inside the cytoplasm. The downstream activity of MAPK1 
in the cytoplasm is also negatively modulated by SEMA6D. 
SEMA6D, on its turn can be negatively modulated as upstream target 
of PLXNA1. Apart from SEMA6D, CAPN1 (calpain 1, (mu/I) 
large subunit) negatively regulates the expression of both PLXNA1 
and SNCA and can thus modulate their downstream actions inside 
the cytoplasm. Semaphorins, secreted proteins involved in the 
guidance of neuronal and nonneuronal cells, interact with receptor 
complexes formed by plexins and neuropilins. There is a literature 
evidence for semaphorins and their receptors to promote or guide 
neuronal axon projection as therapeutic approaches for treatment of 
Parkinson’s disease  [85,86]. Studies in rodent and cell culture models 
of PD suggest that treatment with calpain inhibitors can prevent 
neuronal death and restore functions thus suggesting that calpain 
inhibition could be a therapeutic strategy in PD [87]. 
Third route of the proposed integrated Parkisnon’s disease 
mechanism takes place via another extra-cellular ligand IL12B 
(interleukin 12B) which lies upstream to MAP kinases, RAC1 and 
AKT1, and all these genes negatively regulate the gene expression of 
IL12B. Many studies have suggested that neuroinflammation and 
activated microglia contribute to neurodegenerative processes. 
Interleukins alleviate these harmful effects and help in differentiation 
and survival of neuronal cells that were stressed out by activated 
microglial actions [88,89].  
 
Figure 7. Integrated Parkinson’s disease mechanism. The 46 genes/proteins found in common in all 16 enriched KEGG pathways. Genes/proteins implicated in 
PD pathology are highlighted in green/red and those of potential interest are highlighted in blue/orange, where blue and green colored genes belong to the set 
of significantly modulated genes, while those colored in red and orange are from the set of connecting proteins in shortest path network. Different 
interactions: regulation – dashed grey, molecular transport – dotted red, co-expression – solid blue, protein modification – solid green, protein-protein binding 
– solid purple, promoter binding – dotted green and direct regulation – solid grey. 
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Thus, from the integrated disease mechanism network we present 
a preliminary outline of three possible routes to enhance the survival 
of the dopaminergic neurons, which could be a source for potential 
therapeutic targets in Parkinson’s disease. A more detailed study will 
be needed to elucidate this very complex overall mechanism. 
 
A shortest path network (SPNW) was constructed using all the 
267 seed genes and accounting only for their direct microRNA-
mRNA target interactions as given in the ResNet 9.0 database of 
Pathway Studio software.  71 regulatory miRNAs were thus 
identified (Figure 8).  
Table 5 shows the genes of interest in the MicroRNA Regulatory 
Network (MRN) and how many miRNAs are targeting each gene’s 
mRNA. miR-218-1 was found to be the top player regulating the 
expression of 16 genes of which three (PCDH8, RIMS3 and 
STXBP1) are of potential interest to Parkinson’s disease. In animal 
model study, it was shown that miR-218-1 is expressed in 
hippocampus [90], where volumetric MRI imaging study have found 
a progressive volume loss in PD human subjects [91]. Other 
microRNAs like miR-29a, miR-132, miR-133a1, miR-182, and 
miR-330 were found to regulate the expression of the known 
Parkinson’s related genes ACHE, CX3CL1, FGFR1, L1CAM, and 
SPTAN1. Being direct interacting partners with known PD-related 
genes some of these miRNAs could be considered as potential 
regulatory targets in Parkinson’s disease mechanism. 
The microRNA regulatory network also incorporates some of the 
already implicated miRNA’s (miR-133b, miR-153, miR-34c, miR-7 
and miR-let-7) mediated translation regulations of DJ-1, PARKIN, 
PITX3 and SNCA. These genes are relevant to PD pathophysiology 
being shown to regulate dopaminergic neuron differentiation and 
activity, oxidative stress mediated cell death, and mitochondrial energy 
production dynamics [77–79 ]. 
On further examination, microRNA regulatory network revealed 
that the expression of candidate genes like RIMS3, SEMA6D and 
SYNJ1 was tightly regulated by multiple miRNAs. RIMS3 
(regulating synaptic membrane exocytosis 3) and other RIM family 
members are generally believed to be RAB3 isoforms 
(RAB3A/B/C/D)-specific effectors that regulate synaptic vesicle 
exocytosis in neurons and in some endocrine cells [95]. Release and 
re-uptake of neurotransmitters in the synaptic junction is a highly 
coordinated process and RIMS3, and RAB3A along with other 
proteins play an important role during neurotransmitter release. 
Figure 8. Parkinson’s disease regulatory network. The genes and miRNAs implicated in PD pathology are highlighted in green and the genes of potential 
interest are highlighted in blue. Genes that code for transcription factors (TFs) are highlighted in yellow. MicroRNA-mRNA target interactions are represented 
using solid orange lines.  
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The gene expression of the extra-cellular ligand SEMA6D, 
proposed as one of three initiators of the integrated Parkinson’s 
disease mechanism (Figure 7), was found in our miRNA regulatory 
network to be regulated by seven miRNAs (miR-124-1, miR-128-1, 
miR-16-1, miR-19a, miR-23b, miR-30a and miR-9). Some of those 
like miR-124-1, miR-128-1 and miR-9 have been  previously shown 
of importance for Alzheimer's disease neuropathology being 
abundantly expressed in Alzheimer hippocampus [96]. This may be 
considered as one more sign for the possible existence of common 
regulatory mechanisms in neurodegenerative diseases. 
Another highly microRNA-regulated gene is SYNJ1 
(synaptojanin 1) (see Table 5), a polyphosphoinositide phosphatase 
found enriched in the brain and located at nerve terminals, as well as 
associated with synaptic vesicles and coated endocytic intermediates. 
Synaptojanins were suggested to accelerate the synaptic vesicle 
recovery/trafficking process at the synapse  [97]. Dysfunction of 
synaptic transmission and membrane trafficking are implicated in PD. 
Based on its molecular function, SYNJ1 could play a role in 
Parkinson’s disease molecular mechanism. 
Finally, in addition to miRNA mediated regulation, the network 
also included four genes (AFF1, ATF7IP, ATOH8 and TBC1D2B) 
that encode for transcription factors (TFs). These significantly 
differentially expressed TFs indicate a possible integrated 
TF/miRNA regulation of the transcription of Parkinson’s related 
genes. 
 
4. Summary  
 
The microarray expression data used in our study were a 
combination of data produced and interpreted by different authors 
[33,34] and referring to different regions of brain. With a long-term 
aim to search for a common molecular mechanism for 
neurodegenerative diseases, we renormalized the data for a better 
comparability. Then, a number of specific biomolecular networks 
were built and analyzed in a variety of ways. As a result, while 
confirming some of the previous finding, including part of the novel 
predicted Parkinson’s genes, more such PD-related genes were 
proposed in this work based on guilt-by-association analysis and 
accounting for the importance of certain nodes in network topology.  
As well known, the guilt-by-association approach is based on 
analysis of the nearest network neighborhood of genes with proved 
function in the search of interest. Many Parkinson’s disease genes 
were listed in the OMIM database. However, our list of SDEGs in all 
three Parkinson’s disease datasets used in this study did not include all 
of the OMIM PD-related genes, missing such genes like LRRK2, 
PARK2, PARK7, PLA2G6, PINK1 and UCHL1, while PINK1 and 
UCHL1 were still both significantly expressed in medial Substantia 
nigra, and UCHL1 also in lateral Substantia nigra, but not in all three 
brain tissue types. We found that the log fold-change of PARK2, 
PARK7 and PLA2G6 was only around 0.03, which was not 
significant enough to detect changes in gene expression. Affymetrix 
HG-U133A GeneChip did not contain probe for LRRK2 gene but 
instead included LRRK1 gene probe. Again, LRRK1 did not meet 
the criteria for “seed genes” list since it did not show strong 
differential gene expression and its log fold-change was also only 
around 0.03. While the lack of statistically significant presence of the 
above mentioned PD-related genes could possibly be attributed to the 
loss of expression intensity in the post-mortem brain samples 
compared to a functioning brain, in this study we focused our 
attention mainly to the genes showing considerable change in all three 
selected Parkinson’s disease brain tissue samples. 
Despite the reduced base of 15 known PD-genes needed for the 
guilt-by-association predictions we were able to identify from our 
direct interaction network SYN1 neighboring three known PD genes, 
followed by UBE2N and NCAM1 with two and BSN, PAK1, 
PCHD8, STXBP1, UNC13A and VAMP2 with one such neighbor 
as novel Parkinson’s disease candidate genes. Second-level interacting 
partners generally have much lesser chance to be included in the list of 
candidate genes. However, this chance may increase for some genes 
known to show certain functions that may be related to the disease of 
interest. Such is the case with DCLK1 gene via its role in synaptic 
plasticity and neurodevelopment and as being first neighbor of SYN1. 
Another group of novel PD gene candidates was found from similar 
analysis of the shortest path network. Such is the case with NEDD4L, 
SYNJ1, TUBB3 as direct partners, and ACACB, CACNA1G, 
KCNQ2, and SEMA6D as second-level partners to already known 
PD genes. All 17 genes listed here are significantly differentially 
expressed in PD.  
Our network analysis indicated that apart from the strongly 
differentially expressed genes some connecting genes/proteins from 
the shortest path networks could be of similar importance in the 
deregulation of the disease mechanisms. Considering such connecting 
genes/proteins via their guilt by associations to already known PD 
genes we concluded that CTNNB1, EGFR, ADAM17, CEBPA, 
CTNND1, CDKN1B, KLF1, ROCK1 and TIAM1 could also be 
genes of potential interest in Parkinson’s disease realm. Some of the 
genes of this list were found to play an important role in network 
topology. Thus, CTNNB1 and EGFR are among the top ten highly 
connected nodes (with degree > 15), among the top ten nodes with 
higher accessibility to all other nodes as assessed by the  closeness 
centrality, and among the top ten traffic influential nodes in the 
network as judged by their betweenness centrality. Genes like 
ADAM17, CEBPA and CTNND1 are among the top 25 high 
connectivity nodes (with degree ≥ 8) and also among the top 25 
traffic-influential nodes in the network. Besides helping in identifying 
novel PD-related genes, the same line of network analysis has shown 
that APP, MAPT and PTEN, well-known contributors of many 
other neurodegenerative diseases including Alzheimer’s, MSA, Pick’s, 
PSPs etc., are important connecting genes/proteins in the Parkinson’s 
shortest-path network. Finding such genes with common role in 
neurodegeneration process reinforces our study goal. 
We have also added another seven to the numerous miRNAs 
already known to affect the expression of PD-relevant genes  [92–94]. 
With caution, because some of their regulatory interactions are not 
yet validated, we predict that miR-132, miR-133a1, miR-181-1, 
miR-182, miR-218-1, miR-29a, and miR-330 could be of interest as 
potential regulators in Parkinson’s disease mechanisms, due to their 
direct interaction with known PD related genes. Further investigation 
of the above mentioned miRNA-related regulatory interactions of 
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candidate and known PD-genes would deepen our understanding of 
the molecular mechanisms of complex diseases like Parkinson’s. 
Examining the microRNA regulatory network, one may conclude that 
disease pathogenesis is complex enough and requires regulatory 
mechanisms mediated via both protein-coding genes and the small 
noncoding microRNAs.   
All genes listed in this summary were shown through gene set 
enrichment analysis to be key players in various cellular pathways and 
mechanisms like neuron development and differentiation, synaptic 
transmission, vesicle transport and endocytosis, apoptosis, and 
memory/learning, which are altered in the underlying Parkinson’s 
pathophysiology and the potential compensatory responses. 
Moreover, enrichment of Alzheimer’s, ALS and Huntington’s disease 
signaling pathway was found to take place in PD brains as well. This 
supports the views for the presence of an underlying common 
mechanism for all neurodegenerative diseases.  
In the final stage of our systems biology approach to Parkinson’s 
disease we used the KEGG pathways found enriched by DAVID 
analysis along with the enriched canonical pathways from IPA analysis 
to build an integrated mechanistic Parkinson’s disease network 
containing 46 genes. Three routes of triggering PD molecular 
mechanisms were identified on this basis proceeding from signaling 
initiated via the extra-cellular ligands CX3CL1, SEMA6D and 
IL12B. Further analysis of these routes could reveal novel therapeutic 
targets for Parkinson’s disease. Yet, the above findings could be 
considered only as the tip of the iceberg in understanding the 
intertwined nature of the highly complex neurodegenerative diseases.  
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